Update of the clinical guideline for hypertension diagnosis and treatment in Iran

Bagherikholenjani Fahimeh; Shahidi Shahla; Khosravi Alireza; Mansouri Asieh; Ashoorion Vahid; Sarrafzadegan Nizal; Siavash Mansour; Shahidi Shahrzad; Khorvash Fariborz; Sadeghi Masoumeh; Farshidi Hossein; Assareh Ahmadreza; Jorjani Masoumeh; Badri Shirinsadat; Hajhashemi Valiollah; Hoseinkhani Ramesh; Mortazavi Mojgan; Ghabaei Mojdeh; Khanjani Somayeh; Hashemi Elham; Dehghan Bahar; Davari Majid; Fatemi Behzad; Mohammadifard Noushin; Mobarhan Majid Ghayour; babadi Maryam Eghbali; Ahmadi Alireza; Hassannejad Razieh; Noohi Fereidoun; Kheiri Maryam; Tabatabaeilotfi Mosa; Bakhshandeh Sanaz; Haghighi Azadeh; Mansourian Marjan; Farajzadegan Ziba; Ashraf Hale; Omidi Negar; Tavakolifard Negah; Alizade Mahasti; Vaseghi Golnaz; Nematipour Ebrahim; Ghaffari Samad; Sanjari Mojgan; Shabestari Mahmoud Mohammadzade; Heidarpour Maryam

doi:10.1186/s40885-024-00269-6

추천

검색

자료유형: 학술저널

저자정보: Bagherikholenjani Fahimeh Shahidi Shahla Khosravi Alireza Mansouri Asieh Ashoorion Vahid Sarrafzadegan Nizal Siavash Mansour Shahidi Shahrzad Khorvash Fariborz Sadeghi Masoumeh Farshidi Hossein Assareh Ahmadreza Jorjani Masoumeh Badri Shirinsadat Hajhashemi Valiollah Hoseinkhani Ramesh Mortazavi Mojgan Ghabaei Mojdeh Khanjani Somayeh Hashemi Elham Dehghan Bahar Davari Majid Fatemi Behzad Mohammadifard Noushin Mobarhan Majid Ghayour babadi Maryam Eghbali Ahmadi Alireza Hassannejad Razieh Noohi Fereidoun Kheiri Maryam Tabatabaeilotfi Mosa Bakhshandeh Sanaz Haghighi Azadeh Mansourian Marjan Farajzadegan Ziba Ashraf Hale Omidi Negar Tavakolifard Negah Alizade Mahasti Vaseghi Golnaz Nematipour Ebrahim Ghaffari Samad Sanjari Mojgan Shabestari Mahmoud Mohammadzade Heidarpour Maryam

저널정보: 대한고혈압학회 Clinical Hypertension Clinical Hypertension Vol.30

발행연도: 2024.1

수록면: 13 - 13 (1page)

DOI: 10.1186/s40885-024-00269-6

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

This article introduces the updated version of the Iranian guideline for the diagnosis and treatment of hypertension in adults. The initial version of the national guideline was developed in 2011 and updated in 2014. Among the reasons necessitating the update of this guideline were the passage of time, the incompleteness of the scopes, the limitation of the target group, and more important is the request of the ministry of health in Iran.The members of the guideline updating group, after reviewing the original version and the new evidence, prepared 10 clinical questions regarding hypertension, and based on the evidence found from the latest scientific documents, provided recommendations or suggestions to answer these questions.According to the updated guideline, the threshold for office prehypertension diagnosis should be considered the systolic blood pressure (SBP) of 130-139 mmHg and/or the diastolic blood pressure (DBP) of 80-89 mmHg, and in adults under 75 years of age without comorbidities, the threshold for office hypertension diagnosis should be SBP ≥ 140 mmHg and or DBP ≥ 90 mmHg.The goal of treatment in adults who lack comorbidities and risk factors is SBP < 140 mmHg and DBP < 90 mmHg. The first-line treatment recommended in people with prehypertension is lifestyle modification, while for those with hypertension, pharmacotherapy along with lifestyle modification. The threshold to start drug therapy is determined at SBP ≥ 140 mmHg and or DBP ≥ 90 mmHg, and the first-line treatment is considered a drug or a combined pill of antihypertensive drugs, including ACEIs, ARBs, thiazide and thiazide-like agents, or CCBs.At the beginning of the pharmacotherapy, the Guideline Updating Group members suggested studying serum electrolytes, creatinine, lipid profile, fasting sugar, urinalysis, and an electrocardiogram. Regarding the visit intervals, monthly visits are suggested at the beginning of the treatment or in case of any change in the type or dosage of the drug until achieving the treatment goal, followed by every 3-to-6-month visits. Moreover, to reduce further complications, it was suggested that healthcare unit employees use telehealth strategies.In this guideline, specific recommendations and suggestions have been presented for adults and subgroups like older people or those with cardiovascular disease, diabetes mellitus, chronic kidney disease, and COVID-19.

Background This article introduces the updated version of the Iranian guideline for the diagnosis and treatment of hypertension in adults. The initial version of the national guideline was developed in 2011 and updated in 2014. Among the reasons necessitating the update of this guideline were the passage of time, the incompleteness of the scopes, the limitation of the target group, and more important is the request of the ministry of health in Iran. Method The members of the guideline updating group, after reviewing the original version and the new evidence, prepared 10 clinical questions regarding hypertension, and based on the evidence found from the latest scientifc documents, provided recommendations or suggestions to answer these questions. Result According to the updated guideline, the threshold for ofce prehypertension diagnosis should be considered the systolic blood pressure (SBP) of 130-139 mmHg and/or the diastolic blood pressure (DBP) of 80-89 mmHg, and in adults under 75 years of age without comorbidities, the threshold for ofce hypertension diagnosis should be SBP≥140 mmHg and or DBP≥90 mmHg. The goal of treatment in adults who lack comorbidities and risk factors is SBP<140 mmHg and DBP<90 mmHg. The frst-line treatment recommended in people with prehypertension is lifestyle modifcation, while for those with hypertension, pharmacotherapy along with lifestyle modifcation. The threshold to start drug therapy is determined at SBP≥140 mmHg and or DBP≥90 mmHg, and the frst-line treatment is considered a drug or a combined pill of antihypertensive drugs, including ACEIs, ARBs, thiazide and thiazide-like agents, or CCBs. At the beginning of the pharmacotherapy, the Guideline Updating Group members suggested studying serum electrolytes, creatinine, lipid profle, fasting sugar, urinalysis, and an electrocardiogram. Regarding the visit intervals, monthly visits are suggested at the beginning of the treatment or in case of any change in the type or dosage of the drug until achieving the treatment goal, followed by every 3-to-6-month visits. Moreover, to reduce further complications, it was suggested that healthcare unit employees use telehealth strategies. Conclusions In this guideline, specifc recommendations and suggestions have been presented for adults and subgroups like older people or those with cardiovascular disease, diabetes mellitus, chronic kidney disease, and COVID-19.

#Hypertension #Blood Pressure #Clinical practice Guideline #Updating #Diagnosis #Treatment

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

구분	그룹	데이터 항목
AI 학습용 데이터	원문	원문 PDF 파일
AI 학습용 데이터	원문 + 메타 (기본/상세)	원문 PDF 파일 및 서지정보 CSV
대량 구매용 데이터	B2B 구독 방식	특정 자료 한정으로 원문 접근 권한 부여
대량 구매용 데이터	URL 전달 방식	바로 PDF 뷰어를 열람할 수 있는 URL 제공

구분	그룹	데이터 항목
AI 학습용 데이터	기본 메타	발행기관명, 간행물명, 권호명, 권(vol), 호(issue), 통권, 발행연도, 발행월, 논문명, 저자명, 시작페이지, 종료페이지, 전체페이지, 상세페이지URL
상세 메타 데이터	발행기관 메타	발행기관 이명, 영문명, 창립연도, 홈페이지URL, 발행기관 소개
	간행물 메타	부제목, 간행물 유형, ISSN, ISBN, 최초발행연도, 폐간연도, 간행빈도, 발행주기, 등재사항, 이용수, 피인용수, 권호수, 논문수, 표지이미지
	논문 메타	작성 언어, 부제목, 대등제목, 목차, 키워드, 초록, 이미지, 참고문헌, 이용수, 피인용수, 논문활용도, DBpia통합주제분류, KDC분류, DDC분류, 한국연구재단분류, UCI, DOI
	저자 메타	소속기관, 소속부서, 직급, 연구분야, 연구키워드, 이용수, 피인용수, 저자 논문활용도

구분	그룹	데이터 항목
※ 결합형/맞춤형 메타 데이터는 신청 내용에 따라 다양하게 제공 가능
이용순위 정보	주제분야별 많이 이용된 논문	“인문학”에서 많이 이용된 논문 TOP100
	이용기관별 많이 이용된 논문	“중고등학교”에서 많이 이용된 논문 TOP100
	세부기관별 많이 이용된 논문	“서울대학교”에서 많이 이용된 논문 TOP100
	키워드별 많이 이용된 논문	“Chat GPT”에서 많이 이용된 논문 TOP100
키워드 정보	많이 이용된 키워드	특정기간/분야/저널 내 많이 이용된 키워드
	많이 발행된 키워드	특정기간/분야/저널 내 많이 발행된 키워드
	많이 검색된 키워드	특정기간/분야/저널 내 많이 검색된 키워드
	연구 트렌드 키워드	특정 키워드 연관 연구동향 분석 데이터 키워드

논문 기본 정보

초록· 키워드

AI 요약

연구주제

연구배경

연구방법

연구결과

주요내용

목차

참고문헌 (0)

함께 읽어보면 좋을 논문

최근 본 자료

댓글(0)